---
document_datetime: 2025-12-02 04:54:27
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/elzonris.html
document_name: elzonris.html
version: success
processing_time: 0.1078412
conversion_datetime: 2025-12-27 23:38:27.998978
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Elzonris

[RSS](/en/individual-human-medicine.xml/67358)

##### Authorised

This medicine is authorised for use in the European Union

tagraxofusp Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Elzonris](#news-on)
- [More information on Elzonris](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Elzonris is a medicine used to treat adults with blastic plasmacytoid dendritic cell neoplasm (BPDCN), a type of blood cancer which can affect many organs including the skin, the bone marrow (the spongy tissue inside the large bones) and the lymph nodes.

BPDCN is rare, and Elzonris was designated an 'orphan medicine' (a medicine used in rare diseases) on 11 November 2015.

Expand section

Collapse section

## How is Elzonris used?

Elzonris is available for infusion (drip) into a vein and can only be obtained with a prescription. It should only be given under the supervision of a doctor experienced in the use of cancer medicines, in a setting where resuscitation equipment is available.

The recommended dose is 12 micrograms per kilogram body weight once a day, infused over 15 minutes. Elzonris is given on the first 5 days of a 21-day cycle; cycles are repeated unless the disease gets worse or patients have unacceptable side effects.

The first cycle is given in a hospital, and patients should be monitored for side effects for at least 24 hours after the last infusion. Subsequent cycles can be given in an outpatient setting equipped for intensive monitoring of patients being treated for blood cancer.

Around one hour before each infusion, patients should be given antihistamine medicines, a corticosteroid and paracetamol to lower the risk of allergy-like reactions.

For more information about using Elzonris, see the package leaflet or contact your doctor or pharmacist.

## How does Elzonris work?

The active substance in Elzonris, tagraxofusp, is made up of diphtheria toxin (a substance which is poisonous to cells), linked to a protein called interleukin 3. The interleukin-3 portion of the medicine attaches to receptors (targets) which are found in high number on BPDCN cells. Once attached to cancer cells, the medicine is taken up by them, allowing the toxin to be released inside, which kills them. This is expected to prevent spread of the cancer and reduce symptoms of the disease.

## What benefits of Elzonris have been shown in studies?

Elzonris was investigated in one study involving 84 adults with BPDCN (65 previously untreated, and 19 previously treated with other medicines).

The study showed that 57% (37 out of 65) of previously untreated patients had no signs of disease or had minimal skin damage after treatment with Elzonris. Additionally, about a third (21 out of 65) of these patients were able to have stem cell transplantation (a procedure where the patient's bone marrow is replaced by stem cells from a donor to form new bone marrow that produces healthy cells), which contributed to patients living longer.

## What are the risks associated with Elzonris?

The most common side effects with Elzonris (which may affect more than 1 in 5 people) are hypoalbuminemia (low blood albumin levels), increased blood levels of transaminases (a sign of liver problems), thrombocytopenia (low blood platelet counts), nausea (feeling sick), tiredness and fever.

The most serious side effect that may occur during treatment with Elzonris is capillary leak syndrome (an unpredictable, life-threatening side effect due to small blood vessels becoming leaky), which may affect up to 1 in 5 people.

For the full list of side effects and restrictions of Elzonris, see the package leaflet.

## Why is Elzonris authorised in the EU?

Although the study was small and Elzonris was not compared with other treatments, the European Medicines Agency considered that conducting larger studies for this rare disease is challenging. After considering additional advice from experts in the field, the Agency concluded that the benefits of Elzonris outweigh its risks in patients with BPCDN who had not yet received other treatments and that the medicine can be authorised for use in the EU. However, the data were not sufficient to draw the same conclusion for patients in whom previous treatments did not work. The safety of Elzonris was considered acceptable with specific measures in place to minimise the risk of the most serious side effects.

Elzonris has been authorised under 'exceptional circumstances'. This is because it has not been possible to obtain complete information about Elzonris due to the rarity of the disease. Every year, the Agency will review any new information that becomes available and this overview will be updated as necessary.

## What information is still awaited for Elzonris?

Since Elzonris has been authorised under exceptional circumstances, the company that markets Elzonris will provide the results of a study based on a registry of patients with BPCDN, in order to further characterise the effectiveness and safety of Elzonris.

## What measures are being taken to ensure the safe and effective use of Elzonris?

The company that markets Elzonris will provide educational materials for healthcare professional and an 'alert card' for patients with important information about capillary leak syndrome.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Elzonris have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Elzonris are continuously monitored. Side effects reported with Elzonris are carefully evaluated and any necessary action taken to protect patients.

## Other information about Elzonris

Elzonris received a marketing authorisation under exceptional circumstances valid throughout the EU on 7 January 2021.

Elzonris : EPAR - Medicine overview

Reference Number: EMA/24814/2021

English (EN) (113.74 KB - PDF)

**First published:** 25/01/2021

[View](/en/documents/overview/elzonris-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-49)

български (BG) (140.7 KB - PDF)

**First published:**

25/01/2021

[View](/bg/documents/overview/elzonris-epar-medicine-overview_bg.pdf)

español (ES) (114.35 KB - PDF)

**First published:**

25/01/2021

[View](/es/documents/overview/elzonris-epar-medicine-overview_es.pdf)

čeština (CS) (137.44 KB - PDF)

**First published:**

25/01/2021

[View](/cs/documents/overview/elzonris-epar-medicine-overview_cs.pdf)

dansk (DA) (113.57 KB - PDF)

**First published:**

25/01/2021

[View](/da/documents/overview/elzonris-epar-medicine-overview_da.pdf)

Deutsch (DE) (116.79 KB - PDF)

**First published:**

25/01/2021

[View](/de/documents/overview/elzonris-epar-medicine-overview_de.pdf)

eesti keel (ET) (101.09 KB - PDF)

**First published:**

25/01/2021

[View](/et/documents/overview/elzonris-epar-medicine-overview_et.pdf)

ελληνικά (EL) (141.74 KB - PDF)

**First published:**

25/01/2021

[View](/el/documents/overview/elzonris-epar-medicine-overview_el.pdf)

français (FR) (114.82 KB - PDF)

**First published:**

25/01/2021

[View](/fr/documents/overview/elzonris-epar-medicine-overview_fr.pdf)

hrvatski (HR) (135.36 KB - PDF)

**First published:**

25/01/2021

[View](/hr/documents/overview/elzonris-epar-medicine-overview_hr.pdf)

italiano (IT) (112.16 KB - PDF)

**First published:**

25/01/2021

[View](/it/documents/overview/elzonris-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (143.15 KB - PDF)

**First published:**

25/01/2021

[View](/lv/documents/overview/elzonris-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (134.86 KB - PDF)

**First published:**

25/01/2021

[View](/lt/documents/overview/elzonris-epar-medicine-overview_lt.pdf)

magyar (HU) (134.78 KB - PDF)

**First published:**

25/01/2021

[View](/hu/documents/overview/elzonris-epar-medicine-overview_hu.pdf)

Malti (MT) (137.1 KB - PDF)

**First published:**

25/01/2021

[View](/mt/documents/overview/elzonris-epar-medicine-overview_mt.pdf)

Nederlands (NL) (113.75 KB - PDF)

**First published:**

25/01/2021

[View](/nl/documents/overview/elzonris-epar-medicine-overview_nl.pdf)

polski (PL) (138.23 KB - PDF)

**First published:**

25/01/2021

[View](/pl/documents/overview/elzonris-epar-medicine-overview_pl.pdf)

português (PT) (114.87 KB - PDF)

**First published:**

25/01/2021

[View](/pt/documents/overview/elzonris-epar-medicine-overview_pt.pdf)

română (RO) (134.08 KB - PDF)

**First published:**

25/01/2021

[View](/ro/documents/overview/elzonris-epar-medicine-overview_ro.pdf)

slovenčina (SK) (137.56 KB - PDF)

**First published:**

25/01/2021

[View](/sk/documents/overview/elzonris-epar-medicine-overview_sk.pdf)

slovenščina (SL) (134.31 KB - PDF)

**First published:**

25/01/2021

[View](/sl/documents/overview/elzonris-epar-medicine-overview_sl.pdf)

Suomi (FI) (110.81 KB - PDF)

**First published:**

25/01/2021

[View](/fi/documents/overview/elzonris-epar-medicine-overview_fi.pdf)

svenska (SV) (111.79 KB - PDF)

**First published:**

25/01/2021

[View](/sv/documents/overview/elzonris-epar-medicine-overview_sv.pdf)

Elzonris : EPAR - Risk-management-plan summary

English (EN) (135.07 KB - PDF)

**First published:** 25/01/2021

**Last updated:** 29/07/2022

[View](/en/documents/rmp-summary/elzonris-epar-risk-management-plan-summary_en.pdf)

## Product information

Elzonris : EPAR - Product information

English (EN) (536.02 KB - PDF)

**First published:** 25/01/2021

**Last updated:** 27/10/2025

[View](/en/documents/product-information/elzonris-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-615)

български (BG) (643.37 KB - PDF)

**First published:**

25/01/2021

**Last updated:**

27/10/2025

[View](/bg/documents/product-information/elzonris-epar-product-information_bg.pdf)

español (ES) (669.51 KB - PDF)

**First published:**

25/01/2021

**Last updated:**

27/10/2025

[View](/es/documents/product-information/elzonris-epar-product-information_es.pdf)

čeština (CS) (565.31 KB - PDF)

**First published:**

25/01/2021

**Last updated:**

27/10/2025

[View](/cs/documents/product-information/elzonris-epar-product-information_cs.pdf)

dansk (DA) (629.78 KB - PDF)

**First published:**

25/01/2021

**Last updated:**

27/10/2025

[View](/da/documents/product-information/elzonris-epar-product-information_da.pdf)

Deutsch (DE) (648.33 KB - PDF)

**First published:**

25/01/2021

**Last updated:**

27/10/2025

[View](/de/documents/product-information/elzonris-epar-product-information_de.pdf)

eesti keel (ET) (687.1 KB - PDF)

**First published:**

25/01/2021

**Last updated:**

27/10/2025

[View](/et/documents/product-information/elzonris-epar-product-information_et.pdf)

ελληνικά (EL) (708.27 KB - PDF)

**First published:**

25/01/2021

**Last updated:**

27/10/2025

[View](/el/documents/product-information/elzonris-epar-product-information_el.pdf)

français (FR) (562.26 KB - PDF)

**First published:**

25/01/2021

**Last updated:**

27/10/2025

[View](/fr/documents/product-information/elzonris-epar-product-information_fr.pdf)

hrvatski (HR) (739.23 KB - PDF)

**First published:**

25/01/2021

**Last updated:**

27/10/2025

[View](/hr/documents/product-information/elzonris-epar-product-information_hr.pdf)

íslenska (IS) (528.79 KB - PDF)

**First published:**

25/01/2021

**Last updated:**

27/10/2025

[View](/is/documents/product-information/elzonris-epar-product-information_is.pdf)

italiano (IT) (600.16 KB - PDF)

**First published:**

25/01/2021

**Last updated:**

27/10/2025

[View](/it/documents/product-information/elzonris-epar-product-information_it.pdf)

latviešu valoda (LV) (564.96 KB - PDF)

**First published:**

25/01/2021

**Last updated:**

27/10/2025

[View](/lv/documents/product-information/elzonris-epar-product-information_lv.pdf)

lietuvių kalba (LT) (544.6 KB - PDF)

**First published:**

25/01/2021

**Last updated:**

27/10/2025

[View](/lt/documents/product-information/elzonris-epar-product-information_lt.pdf)

magyar (HU) (760.7 KB - PDF)

**First published:**

25/01/2021

**Last updated:**

27/10/2025

[View](/hu/documents/product-information/elzonris-epar-product-information_hu.pdf)

Malti (MT) (605.68 KB - PDF)

**First published:**

25/01/2021

**Last updated:**

27/10/2025

[View](/mt/documents/product-information/elzonris-epar-product-information_mt.pdf)

Nederlands (NL) (502.62 KB - PDF)

**First published:**

25/01/2021

**Last updated:**

27/10/2025

[View](/nl/documents/product-information/elzonris-epar-product-information_nl.pdf)

norsk (NO) (501.81 KB - PDF)

**First published:**

25/01/2021

**Last updated:**

27/10/2025

[View](/no/documents/product-information/elzonris-epar-product-information_no.pdf)

polski (PL) (597.75 KB - PDF)

**First published:**

25/01/2021

**Last updated:**

27/10/2025

[View](/pl/documents/product-information/elzonris-epar-product-information_pl.pdf)

português (PT) (537.52 KB - PDF)

**First published:**

25/01/2021

**Last updated:**

27/10/2025

[View](/pt/documents/product-information/elzonris-epar-product-information_pt.pdf)

română (RO) (571.21 KB - PDF)

**First published:**

25/01/2021

**Last updated:**

27/10/2025

[View](/ro/documents/product-information/elzonris-epar-product-information_ro.pdf)

slovenčina (SK) (547.99 KB - PDF)

**First published:**

25/01/2021

**Last updated:**

27/10/2025

[View](/sk/documents/product-information/elzonris-epar-product-information_sk.pdf)

slovenščina (SL) (593.46 KB - PDF)

**First published:**

25/01/2021

**Last updated:**

27/10/2025

[View](/sl/documents/product-information/elzonris-epar-product-information_sl.pdf)

Suomi (FI) (712.21 KB - PDF)

**First published:**

25/01/2021

**Last updated:**

27/10/2025

[View](/fi/documents/product-information/elzonris-epar-product-information_fi.pdf)

svenska (SV) (537.59 KB - PDF)

**First published:**

25/01/2021

**Last updated:**

27/10/2025

[View](/sv/documents/product-information/elzonris-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** R/0000261300 17/09/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Elzonris : EPAR - All authorised presentations

English (EN) (14.52 KB - PDF)

**First published:** 25/01/2021

[View](/en/documents/all-authorised-presentations/elzonris-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-913)

български (BG) (51.91 KB - PDF)

**First published:**

25/01/2021

[View](/bg/documents/all-authorised-presentations/elzonris-epar-all-authorised-presentations_bg.pdf)

español (ES) (21.3 KB - PDF)

**First published:**

25/01/2021

[View](/es/documents/all-authorised-presentations/elzonris-epar-all-authorised-presentations_es.pdf)

čeština (CS) (34.78 KB - PDF)

**First published:**

25/01/2021

[View](/cs/documents/all-authorised-presentations/elzonris-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (16.1 KB - PDF)

**First published:**

25/01/2021

[View](/da/documents/all-authorised-presentations/elzonris-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (16.43 KB - PDF)

**First published:**

25/01/2021

[View](/de/documents/all-authorised-presentations/elzonris-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (16.47 KB - PDF)

**First published:**

25/01/2021

[View](/et/documents/all-authorised-presentations/elzonris-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (38.59 KB - PDF)

**First published:**

25/01/2021

[View](/el/documents/all-authorised-presentations/elzonris-epar-all-authorised-presentations_el.pdf)

français (FR) (16.52 KB - PDF)

**First published:**

25/01/2021

[View](/fr/documents/all-authorised-presentations/elzonris-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (32.07 KB - PDF)

**First published:**

25/01/2021

[View](/hr/documents/all-authorised-presentations/elzonris-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (21.49 KB - PDF)

**First published:**

25/01/2021

[View](/is/documents/all-authorised-presentations/elzonris-epar-all-authorised-presentations_is.pdf)

italiano (IT) (16.54 KB - PDF)

**First published:**

25/01/2021

[View](/it/documents/all-authorised-presentations/elzonris-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (37.59 KB - PDF)

**First published:**

25/01/2021

[View](/lv/documents/all-authorised-presentations/elzonris-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (33.67 KB - PDF)

**First published:**

25/01/2021

[View](/lt/documents/all-authorised-presentations/elzonris-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (24 KB - PDF)

**First published:**

25/01/2021

[View](/hu/documents/all-authorised-presentations/elzonris-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (35.79 KB - PDF)

**First published:**

25/01/2021

[View](/mt/documents/all-authorised-presentations/elzonris-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (21.47 KB - PDF)

**First published:**

25/01/2021

[View](/nl/documents/all-authorised-presentations/elzonris-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (16.62 KB - PDF)

**First published:**

25/01/2021

[View](/no/documents/all-authorised-presentations/elzonris-epar-all-authorised-presentations_no.pdf)

polski (PL) (36 KB - PDF)

**First published:**

25/01/2021

[View](/pl/documents/all-authorised-presentations/elzonris-epar-all-authorised-presentations_pl.pdf)

português (PT) (16.48 KB - PDF)

**First published:**

25/01/2021

[View](/pt/documents/all-authorised-presentations/elzonris-epar-all-authorised-presentations_pt.pdf)

română (RO) (35.28 KB - PDF)

**First published:**

25/01/2021

[View](/ro/documents/all-authorised-presentations/elzonris-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (33.99 KB - PDF)

**First published:**

25/01/2021

[View](/sk/documents/all-authorised-presentations/elzonris-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (24.2 KB - PDF)

**First published:**

25/01/2021

[View](/sl/documents/all-authorised-presentations/elzonris-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (14.39 KB - PDF)

**First published:**

25/01/2021

[View](/fi/documents/all-authorised-presentations/elzonris-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (16.51 KB - PDF)

**First published:**

25/01/2021

[View](/sv/documents/all-authorised-presentations/elzonris-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Elzonris Active substance tagraxofusp International non-proprietary name (INN) or common name tagraxofusp Therapeutic area (MeSH) Lymphoma Anatomical therapeutic chemical (ATC) code L01XX67

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Elzonris is indicated as monotherapy for the first-line treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN).

## Authorisation details

EMA product number EMEA/H/C/005031

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Exceptional circumstances

This medicine was authorised under exceptional circumstances, because the applicant was unable to provide comprehensive data on the efficacy and safety of the medicine under normal conditions of use. This can happen because the condition to be treated is rare or because collection of full information is not possible or is unethical. For more information, see [Pre-authorisation guidance](/node/68554) .

Orphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see [Orphan designation](/node/69983) .

Marketing authorisation holder

Stemline Therapeutics B.V.

Basisweg 10

Opinion adopted 12/11/2020 Marketing authorisation issued 07/01/2021 Revision 8

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Elzonris : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (143.27 KB - PDF)

**First published:** 27/10/2025

[View](/en/documents/procedural-steps-after/elzonris-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Elzonris : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (130.22 KB - PDF)

**First published:** 08/11/2021

**Last updated:** 27/10/2025

[View](/en/documents/procedural-steps-after/elzonris-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Elzonris : Orphan maintenance assessment report (initial authorisation)

Adopted

Reference Number: EMADOC-1700519818-591283

English (EN) (231.03 KB - PDF)

**First published:** 25/01/2021

[View](/en/documents/orphan-maintenance-report/elzonris-orphan-maintenance-assessment-report-initial-authorisation_en.pdf)

Elzonris : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/24699/2021

English (EN) (14.64 MB - PDF)

**First published:** 25/01/2021

[View](/en/documents/assessment-report/elzonris-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Elzonris

Adopted

Reference Number: EMA/CHMP/597095/2020

English (EN) (114.06 KB - PDF)

**First published:** 13/11/2020

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-elzonris_en.pdf)

#### News on Elzonris

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 November 2020](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-9-12-november-2020) 13/11/2020

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 September 2020](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-14-17-september-2020) 18/09/2020

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 July 2020](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-july-2020) 24/07/2020

#### More information on Elzonris

- [EU/3/15/1567 - orphan designation for treatment of blastic plasmacytoid dendritic cell neoplasm](/en/medicines/human/orphan-designations/eu-3-15-1567)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 27/10/2025

## Share this page

[Back to top](#main-content)